The Effect of Outpatient Ketamine Infusion on Chronic Neuropathic Pain and PTSD
RecruitingPhase 4NCT06414356
View the official record on ClinicalTrials.gov Recruiting status changes often. Contact the study team listed on ClinicalTrials.gov, and talk to your doctor before joining a study.
This study has no listed site in Canada in this snapshot. It is included as part of the worldwide chronic pain corpus.
Brief summary (from the registry)
This study is aimed to evaluate outpatient ketamine infusion within a military chronic neuropathic pain population and its effect on PTSD. Currently, this is a pilot study with 30 participants. Participants will be randomized to (1) a moderate dose ketamine, (2) moderate dose ketamine +Mg, or (3) a magnesium control group. Participants will complete self-reported pain and PTSD questionnaires throughout the \~24-week study period. The outlined strategy will provide evidence for the utility of ketamine in neuropathic pain management and pain associated comorbidities within a military population.
Study details
- Official title
- The Effect of Outpatient Ketamine Infusion on Chronic Neuropathic Pain and PTSD: A Prospective Randomized Design
- Conditions
- Interventions
- Drug: Ketamine
- Drug: Magnesium sulfate
- Drug: Ketamine + Magnesium sulfate
- Sponsor
- Margaux M. Salas, PhD
- Organization
- Brooke Army Medical Center
- Start date
- 2024-10-02
- Primary completion
- 2025-04
- Sex
- All
- Age range
- from 18 Years to 70 Years
- Healthy volunteers
- true
- Results posted
- No results posted in this snapshot
- Countries
- United States
- Total sites listed
- 1
Eligibility criteria
Show eligibility criteria (verbatim from the registry)
Inclusion Criteria: * 18-70 years old with Chronic Neuropathic Pain \>= 3 months * Biologic male or biologic female * Women of childbearing age will be included if there are no plans of pregnancy within the study period, the participant agrees to actively utilize contraception throughout the study, and agrees to pregnancy tests * Active Duty, Veterans, and retirees * Ketamine naïve for 1 year * Moderate Neuropathic pain Scale 4-7 Exclusion Criteria: * Cognitive dysfunction * Psychiatric illness involving psychosis * Neurocognitive disorder * Patients with Traumatic Brain Injury (TBI) * Acute cardiovascular disease or poorly controlled hypertension * Untreated or uncontrolled thyroid disease * Hyperthyroidism * Severe liver or renal disease * Renal impairment * History of recent heart attack, vascular disease, or any other medical condition that may be deemed by a provider as a contraindication to receiving ketamine * Active substance abuse * Pregnant or lactating * Patients who are planning to become pregnant within 12 weeks of treatment completion * Elevated Blood Pressure/hypertension * Known hypersensitivity to Ketamine * Hemodynamic instability * Respiratory depression * Use of Theophylline or Aminophylline, Sympathomimetics and Vasopressin, * Use of Benzodiazepines * A history of drug abuse or dependence * Active risk of substance use * Patients who are not able to abide by the pre-treatment and posttreatment clinical protocol, such as food intake, abstaining from certain medications, unable to remain in the clinic for a minimum of 1 hour for observation, and cannot provide the name and phone number of the party who will pick them up post-treatment
Source: ClinicalTrials.gov (US National Library of Medicine), snapshot October 2026. Check the registry for current recruiting status. Record: https://clinicaltrials.gov/study/NCT06414356